Adding belzutifan or a CTLA-4 drug to Keytruda plus Lenvima did not improve survival at an interim look in advanced kidney cancer. Full data come Oct. 25.
Adding Belzutifan or a CTLA-4 Drug Failed to Beat Keytruda Plus Lenvima in 1,688-Patient Kidney Cancer Trial
by | Oct 25, 2026 | Uncategorized | 0 comments
Recent Comments